European award for medicinal chemists: New active ingredients for the treatment of infections

Martin Empting works towards the development of new active substances that can be used to treat bacterial and viral infections. He has now been awarded the Young Medicinal Chemist in Academia Prize by the European Federation of Medicinal Chemistry (EFMC) as a runner-up. This prize is aimed at young chemists who are pursuing a career in academic research.

Background Research:

Martin Empting is a distinguished researcher who has dedicated his career to the development of new active ingredients that can counter bacterial and viral infections. He currently works in academia, striding forward with ambitious research projects carried out with great diligence.

In Europe, he became a runner-up for the „Young Medicinal Chemist in Academia Prize“. This esteemed award is offered by the European Federation of Medicinal Chemistry (EFMC) to young chemists pursuing groundbreaking work in their academic research. The EFMC serves as an umbrella organization for numerous European societies specializing in medicinal chemistry and brings together experienced professionals from academia, industry, and regulatory authorities.

FAQs:

1. Who is Martin Empting?
Martin Empting is an ambitious researcher working on the development of new substances that can be used to treat various bacterial and viral infections.

2. What recognition has he received recently?
He has been awarded as a runner-up for the Young Medicinal Chemist in Academia Prize by the European Federation of Medicinal Chemistry (EFMC).

3. What type of work does this prize recognize?
The prize recognizes remarkable research efforts undertaken by young chemists involved in academic studies with potential societal impact.

4. What does Mr Empting’s achievement mean?
His recent attainment signifies professional recognition trialed at high standards held by EFMC – it highlights his significant contributions towards finding innovative solutions to treat infectious diseases.

5.What are these active substances he’s developing doing?
These active substances are aimed at combating harmful bacteria and viruses which cause health problems – potentially they could pave way for advanced medicines effective against diverse set of diseases.

6.What’s unique about this award?
This award imparts recognition specifically within Europe’s scientific community engaged in medicinal chemistry, favoring outstanding individuals constantly striving toward uprooting healthcare issues via innovative methods.

7.Who offers this Young Medicinal Chemist in Academia Prize?
The European Federation of Medicinal Chemistry (EFMC) confers this award.

8.What does the EFMC do?
The EFMC is an organization made up of multiple European societies that specialize in medicinal chemistry. This collective body includes professionals from academia, industry, and regulatory authorities working together towards better health-based solutions.

Originamitteilung:

Martin Empting works towards the development of new active substances that can be used to treat bacterial and viral infections. He has now been awarded the Young Medicinal Chemist in Academia Prize by the European Federation of Medicinal Chemistry (EFMC) as a runner-up. This prize is aimed at young chemists who are pursuing a career in academic research.

share this recipe:
Facebook
Twitter
Pinterest

Weitere spannende Artikel

Gutes Komplikationsmanagement nach Operationen – Warum die Failure-to-Rescue-Rate im Qualitätsbericht stehen sollte

Patientinnen und Patienten sollten bei der Wahl ihres Krankenhauses nicht nur auf die Erfahrung des Operateurs achten. Denn gerade bei komplexen und risikoreichen Eingriffen kommt es neben dem erfolgreichen Eingriff auch auf das Beherrschen der Komplikationen an, die danach auftreten können. Diese Zahl gibt die sogenannte Failure to Rescue (FTR= Rettungsversagen) – Rate wieder: Sie besagt, dass eine lebensbedrohliche Komplikation nicht rechtzeitig erkannt oder nicht adäquat behandelt wurde und im schlechtesten Fall zum Tod geführt hat.

Read More

Das Gehirn bewegt sich, wenn wir es tun. DFG fördert Kooperation zu Ortszellen und räumlichem Lernen

Forschende aus Magdeburg und Erlangen untersuchen gemeinsam, wie unser Gehirn lernt, sich in Räumen zu orientieren und Erinnerungen speichert. Am Leibniz-Institut für Neurobiologie (LIN) analysieren Wissenschaftler:innen, wie Neuronen im Hippocampus unser räumliches Lernen steuern. Dafür nehmen sie im Zeitraffer auf, was im Gehirn von Mäusen geschieht, während sie verschiedene Orientierungsaufgaben lösen. So gewinnen sie umfangreiche Daten, die im zweiten Schritt von Kooperationspartnern an der Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) mit einem eigens entwickelten KI-Tool ausgewertet werden.

Read More